Elixxer

Elixxer CROIC

The Cash Return on Invested Capital (CROIC) of Elixxer (ELXR.H.V) as of Nov 4, 2026 is -4,186.04 %. In the previous year, Cash Return on Invested Capital (CROIC) was -123.98 % — a change of 3,276.49% (lower).

CROIC

-4,186.04 %

YoY

3,276.49%

Last updated:

Cash Return on Invested Capital (CROIC) of Elixxer is 2023 -4,186.04 % . Cash Return on Invested Capital (CROIC) of Elixxer was 2022 -123.98 % . It decreases by 3,276.49% lower compared to the previous year.

The Elixxer CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2016
-58.75 CAD
Jan 1, 2017
-139.73 CAD
Jan 1, 2018
-22.84 CAD
Jan 1, 2019
-37.11 CAD
Jan 1, 2020
-16.88 CAD
Jan 1, 2021
-26.93 CAD
Jan 1, 2022
-123.98 CAD
Jan 1, 2023
-4,186.04 CAD
The Elixxer CROIC history
YEARCROICYoY
-4,186.04 %+3,276.49%
-123.98 %+360.42%
-26.93 %+59.54%
-16.88 %-54.52%
-37.11 %+62.48%
-22.84 %-83.65%
-139.73 %+137.83%
-58.75 %-97.37%
-2,233.33 %+4,199.19%
-51.95 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Elixxer Stock analysis

What does Elixxer do? Elixxer Ltd. invests in cannabis-related businesses licensed for cultivation, production, and sale of cannabis and cannabis-derived products. The company focuses on medical cannabis and specialty pharmaceutical products, growing and producing medical-grade cannabis for global markets. Its brands include Viridi, Easyjoint, Freia, Little Green Pharma (LGP), and One Premium Cannabis, which are used for CBD cosmetics, natural wellness products, and pharmaceutical applications. Elixxer targets medical and wellness segments through its subsidiaries in Australia, Canada, Switzerland, Italy, and Jamaica, where it operates cultivation, extraction, and production facilities for legal cannabis products. The company generates revenue through its portfolio of cannabis investments, including nutraceutical, cosmetics, and pharmaceutical segments. Its subsidiaries LGC Finance Limited, LGC Capital EU OU, and LGC Capital Spain S.L. support its global operations, while its brands cater to consumers seeking CBD-based wellness solutions and medical cannabis products. Elixxer's focus on medical cannabis and pharmaceutical applications drives its market positioning in the global cannabis industry. Elixxer Ltd. primarily serves medical and specialty cannabis markets, with a strong emphasis on pharmaceutical-grade products. Its investments span cultivation, extraction, and production facilities across multiple countries, enabling it to supply global markets with medical cannabis and CBD-derived products. The company's brands are positioned within the wellness and pharmaceutical sectors, targeting consumers and healthcare providers interested in natural and medical cannabis solutions. Elixxer is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Elixxer stock

Cash Return on Invested Capital (CROIC) of Elixxer is -4,186.04 % in 2023.

Cash Return on Invested Capital (CROIC) of Elixxer changed from -123.98 % to -4,186.04 %, representing a 3,276.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Elixxer since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Elixxer with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Elixxer

All Key Metrics — Elixxer